InhaleRx Unveils Oral Esketamine SRX-25 to Transform Depression Treatment

• Launch of SRX-25 oral Esketamine and CYP450 inhibitor combo for Treatment-Resistant Depression
• Development via FDA 505(b)(2) pathway with planned Phase 1 and Phase 2 trials
• Secured $750,000 placement and $250,000 rights issue to fund development
• Backing from Linlithgow Family Office with $12.6 million funding commitment